J2H-1702 / J2HBiotech - LARVOL DELTA

Inhibition of 11β-hydroxysteroid dehydrogenase 1 alleviates pulmonary fibrosis through inhibition of endothelial-to-mesenchymal transition and M2 macrophage polarization by upregulating heme oxygenase-1. (PubMed, Cell Death Dis) - "In mouse models of pulmonary fibrosis, including a bleomycin-induced idiopathic model and a radiation-induced model, J2H-1702 alleviated pulmonary fibrosis and markedly improved the efficacy of nintedanib. Collectively, our data suggest that J2H-1702 holds promise as a clinical candidate for the treatment of pulmonary fibrosis associated with reactive oxygen species-induced DNA damage, endothelial-to-mesenchymal transition, and inflammatory responses."

Journal • Diabetes • Genetic Disorders • Hepatitis B • Hepatology • Immunology • Lung Cancer • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Type 2 Diabetes Mellitus • HMOX1 • IL1B

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: J2H Biotech | Trial completion date: Jan 2025 ➔ Oct 2025 | Trial primary completion date: Jan 2025 ➔ Apr 2025

Trial completion date • Trial primary completion date • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

Role of 11β-hydroxysteroid dehydrogenase type 1 inhibition in the antiobesity effect of J2H-1702 on adipocytes and a high-fat diet-induced NASH model. (PubMed, Eur J Pharmacol) - "We tested the potential of J2H-1702 as a therapeutic agent for NASH using a high-fat diet-induced NASH model, with obeticholic acid, an FXR agonist, and elafibranor as reference drugs. All drugs significantly decreased the elevated triglyceride levels in the livers of high-fat, high-carbohydrate (HFHC-fed mice. The results may add to the benefits of targeting 11β-HSD1 inhibitors with antiadipogenic activity in developing a therapeutic agent for obesity treatment."

Journal • Genetic Disorders • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • AKT1 • CDH1 • CDH2 • MAPK8 • PPARA • PROS1 • TGFB1

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males (clinicaltrials.gov) - P1 | N=100 | Completed | Sponsor: J2H Biotech

New P1 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

Phase 1 Study to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: J2H Biotech

New P1 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: J2H Biotech

New P2 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment. (PubMed, Aliment Pharmacol Ther) - "The results of this study suggest that J2H-1702 could be developed as an effective therapeutic option for NASH."

Journal • P1 data • Addiction (Opioid and Alcohol) • Hepatology • Inflammation • Non-alcoholic Steatohepatitis

Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH. (PubMed, Cell Death Dis) - "Of great interest, the 11βHSD1 inhibitor J2H-1702 significantly attenuated hepatic lipid accumulation and ameliorated liver fibrosis in diet- and toxicity-induced NASH mouse models. Together, our data indicate that J2H-1702 is a promising new clinical candidate for the treatment of NASH."

Journal • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Non-alcoholic Steatohepatitis • Obesity • CD61 • COL1A1 • PPARA • SMAD3 • TLR7

Inhibition of 11beta-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH (EASL-ILC 2022) - "Together, our data indicate that J2H-1702 is a promising new clinical candidate for the treatment of NASH."

Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Non-alcoholic Steatohepatitis • Obesity • CD61 • COL1A1 • SMAD3 • TLR7